Navulizumab is available in two dosage forms, 40mg and 100mg, and the price may vary slightly in different regions, with 40mg costing around 5,000RMB per dose and 100mg costing around 10,000RMB per dose. Navulizumab is a PD-1 inhibitor, belonging to the immune checkpoint inhibitor class of anti-tumor immunity drugs. Navulizumab is mainly used in the treatment of advanced non-small cell lung cancer, advanced gastric or gastroesophageal junction adenocarcinoma, advanced head and neck squamous carcinoma and other malignant tumors. When clinically using Navulizumab, the dosage can be fixed at 240mg or 360mg, and the dosage can also be selected according to the different body weights of the patients, for example, 100mg is selected for patients weighing about 35kg, and 140mg is selected for patients weighing 40-50kg, and so on. As an anti-tumor immune drug, its use must be guided by a professional doctor.